These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 26337818

  • 41. Regulation of aquaporin-2 trafficking.
    Nedvetsky PI, Tamma G, Beulshausen S, Valenti G, Rosenthal W, Klussmann E.
    Handb Exp Pharmacol; 2009; (190):133-57. PubMed ID: 19096775
    [Abstract] [Full Text] [Related]

  • 42. Congenital nephrogenic diabetes insipidus: what can we learn from mouse models?
    Boone M, Deen PM.
    Exp Physiol; 2009 Feb; 94(2):186-90. PubMed ID: 18790812
    [Abstract] [Full Text] [Related]

  • 43. Aquaporin 2 mutations in nephrogenic diabetes insipidus.
    Loonen AJ, Knoers NV, van Os CH, Deen PM.
    Semin Nephrol; 2008 May; 28(3):252-65. PubMed ID: 18519086
    [Abstract] [Full Text] [Related]

  • 44. p.R254Q mutation in the aquaporin-2 water channel causing dominant nephrogenic diabetes insipidus is due to a lack of arginine vasopressin-induced phosphorylation.
    Savelkoul PJ, De Mattia F, Li Y, Kamsteeg EJ, Konings IB, van der Sluijs P, Deen PM.
    Hum Mutat; 2009 Oct; 30(10):E891-903. PubMed ID: 19585583
    [Abstract] [Full Text] [Related]

  • 45. Development of lithium-induced nephrogenic diabetes insipidus is dissociated from adenylyl cyclase activity.
    Li Y, Shaw S, Kamsteeg EJ, Vandewalle A, Deen PM.
    J Am Soc Nephrol; 2006 Apr; 17(4):1063-72. PubMed ID: 16495377
    [Abstract] [Full Text] [Related]

  • 46. Lack of arginine vasopressin-induced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus.
    de Mattia F, Savelkoul PJ, Kamsteeg EJ, Konings IB, van der Sluijs P, Mallmann R, Oksche A, Deen PM.
    J Am Soc Nephrol; 2005 Oct; 16(10):2872-80. PubMed ID: 16120822
    [Abstract] [Full Text] [Related]

  • 47. Do aquaporins have a role in nocturnal enuresis?
    Frøkiaer J, Nielsen S.
    Scand J Urol Nephrol Suppl; 1997 Oct; 183():31-2. PubMed ID: 9165602
    [Abstract] [Full Text] [Related]

  • 48. Repulsion between Lys258 and upstream arginines explains the missorting of the AQP2 mutant p.Glu258Lys in nephrogenic diabetes insipidus.
    Kamsteeg EJ, Stoffels M, Tamma G, Konings IB, Deen PM.
    Hum Mutat; 2009 Oct; 30(10):1387-96. PubMed ID: 19701945
    [Abstract] [Full Text] [Related]

  • 49. Bendamustine-Induced Nephrogenic Diabetes Insipidus in a Patient With AL Amyloidosis.
    Uwumugambi NA, Sanchorawala V, Shelton AC, Stern L, Gordon CE.
    Am J Kidney Dis; 2017 Feb; 69(2):317-319. PubMed ID: 27780577
    [Abstract] [Full Text] [Related]

  • 50. Protective effect of metformin on lithium-induced nephrogenic diabetes insipidus: An experimental study in rats.
    Tas HI, Sancak EB.
    Adv Clin Exp Med; 2021 Nov; 30(11):1185-1193. PubMed ID: 34595852
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Variations in daily urine solute output in patients with NDI, CDI, SIADH, and NSIAD: Clinical implications.
    Decaux G.
    Clin Nephrol; 2021 Oct; 96(4):233-238. PubMed ID: 34236307
    [Abstract] [Full Text] [Related]

  • 54. Vasopressin-independent regulation of collecting duct aquaporin-2 in food deprivation.
    Wilke C, Sheriff S, Soleimani M, Amlal H.
    Kidney Int; 2005 Jan; 67(1):201-16. PubMed ID: 15610244
    [Abstract] [Full Text] [Related]

  • 55. Treatment of congenital nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride in an adult patient.
    Konoshita T, Kuroda M, Kawane T, Koni I, Miyamori I, Tofuku Y, Mabuchi H, Takeda R.
    Horm Res; 2004 Jan; 61(2):63-7. PubMed ID: 14646392
    [Abstract] [Full Text] [Related]

  • 56. A novel therapeutic effect of statins on nephrogenic diabetes insipidus.
    Bonfrate L, Procino G, Wang DQ, Svelto M, Portincasa P.
    J Cell Mol Med; 2015 Feb; 19(2):265-82. PubMed ID: 25594563
    [Abstract] [Full Text] [Related]

  • 57. [Congenital nephrogenic diabetes insipidus: about a case report].
    Esselmani H, Yassine A, Bouabdellah M, Benchekroun L, Handor N, Elalami S, Chabraoui L.
    Ann Biol Clin (Paris); 2013 Feb; 71(2):241-5. PubMed ID: 23587596
    [Abstract] [Full Text] [Related]

  • 58. Congenital nephrogenic diabetes insipidus presenting as osmotic demyelination syndrome in infancy: A case report.
    Kobayashi S, Mizuno N, Yokoi K, Mori T, Sohara E, Uchida S.
    Medicine (Baltimore); 2022 Jan 21; 101(3):e28552. PubMed ID: 35060513
    [Abstract] [Full Text] [Related]

  • 59. Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial.
    Fotso Soh J, Torres-Platas SG, Beaulieu S, Mantere O, Platt R, Mucsi I, Saury S, Renaud S, Levinson A, Andreazza AC, Mulsant BH, Müller D, Schaffer A, Dols A, Cervantes P, Low NC, Herrmann N, Christensen BM, Trepiccione F, Rajji T, Rej S.
    BMC Psychiatry; 2018 Jul 16; 18(1):227. PubMed ID: 30012135
    [Abstract] [Full Text] [Related]

  • 60. Water transport in the kidney and nephrogenic diabetes insipidus.
    Cohen M, Post GS.
    J Vet Intern Med; 2002 Jul 16; 16(5):510-7. PubMed ID: 12322698
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.